Liraglutide: new indication for cardiovascular risk reduction
Per the manufacturer, liraglutide just received a new indication by the FDA: "to reduce the risk of major adverse cardiovascular (CV) events, heart attack, stroke and CV death, in adults with type 2 diabetes and established CV disease". see http://press.novonordisk-us.com/2017-08-25-Victoza-R-liraglutide-is-approved-in-the-US-as-the-only-type-2-diabetes-treatment-indicated-to-reduce-the-risk-of-three-major-adverse-cardiovascular-events will append my blog below from 6/22/16, which reviewed the original article leading to this indication, and my commentary: there was a recent article from a paper at the Am Diabetes Assn annual meeting finding decreased cardiovascular events in patients on the glucagon-like peptide 1 (GLP-1) agonist liraglutide (see DOI: 10.1056/NEJMoa1603827). details : --9340 patients with type 2 diabetes and high cardiovascular risk, randomized to liraglutide vs placebo, with mean follo...